Results 21 to 30 of about 32,786 (220)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group [PDF]

Circulation: Heart Failure, 2022
Immunoglobulin light chain amyloidosis is a rare, multisystemic, phenotypically heterogenous disease affecting cardiovascular, renal, neurological, and gastrointestinal systems to varying degrees.
Mathew S Maurer, Ronald Witteles, Claudio Rapezzi   +2 more
exaly   +4 more sources

Immunoglobulin light chain amyloidosis [PDF]

memo - Magazine of European Medical Oncology, 2021
Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains.
H. Agis, M. Krauth
semanticscholar   +2 more sources

Immunoglobulin light chain amyloidosis

Expert Review of Hematology, 2014
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function.
Gertz MA, Comenzo RL, Seldin DC, MERLINI, GIAMPAOLO, Wechalekar A   +4 more
core   +4 more sources

Localized Lymph Node Light Chain Amyloidosis [PDF]

Case Reports in Hematology, 2015
Immunoglobulin-derived light chain amyloidosis can occasionally be associated with localized disease. We present a patient with localized lymph node light chain amyloidosis without an underlying monoclonal protein or lymphoproliferative disorder and ...
Binod Dhakal, Alexandra M. Harrington, Michael E. Stadler, Anita D’Souza   +3 more
doaj   +2 more sources

Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis. [PDF]

Hematol Oncol Clin North Am, 2020
Stem cell transplantation was one of the first proven effective regimens for the management of immunoglobulin light-chain amyloidosis. Criteria for patient selection and the mobilization regimen become important features in ensuring a safe outcome.
Gertz MA, Schonland S.
europepmc   +2 more sources

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

JAMA Oncol
Importance Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is ...
Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA.   +30 more
europepmc   +2 more sources

Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.

PLoS ONE, 2020
Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis is caused by a misfolded light chain produced by a clonal population of plasma cells.
Elaine C Chen, Samuel Rubinstein, Cinque Soto, Robin G Bombardi, Samuel B Day, Luke Myers, Alexey Zaytsev, Mahsa Majedi, R Frank Cornell, James E Crowe   +9 more
doaj   +2 more sources

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. [PDF]

Blood Cancer J, 2020
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalidomide-
Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A.   +25 more
europepmc   +2 more sources

An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis

Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis
Background Each monoclonal antibody light chain associated with AL amyloidosis has a unique sequence. Defining how these sequences drive amyloid deposition could facilitate faster diagnosis and lead to new treatments.
Gareth J Morgan, Sherry Wong, Brian H Spencer   +2 more
exaly   +3 more sources

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. [PDF]

Blood Cancer J, 2023
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A.   +5 more
europepmc   +2 more sources